- Home
- TRUG vs IBIO Comparison
TRUG vs IBIO Comparison
Compare TRUG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- IBIO
- Stock Information
- Founded
- TRUG 1983
- IBIO 2008
- Country
- TRUG United States
- IBIO United States
- Employees
- TRUG N/A
- IBIO N/A
- Industry
- TRUG
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- IBIO Health Care
- Exchange
- TRUG NYSE
- IBIO Nasdaq
- Market Cap
- TRUG 10.9M
- IBIO 9.3M
- IPO Year
- TRUG N/A
- IBIO N/A
- Fundamental
- Price
- TRUG $0.23
- IBIO $0.73
- Analyst Decision
- TRUG Strong Buy
- IBIO Strong Buy
- Analyst Count
- TRUG 1
- IBIO 3
- Target Price
- TRUG $2.00
- IBIO $4.87
- AVG Volume (30 Days)
- TRUG 1.8M
- IBIO 2.3M
- Earning Date
- TRUG 04-15-2025
- IBIO 05-02-2025
- Dividend Yield
- TRUG N/A
- IBIO N/A
- EPS Growth
- TRUG N/A
- IBIO N/A
- EPS
- TRUG N/A
- IBIO N/A
- Revenue
- TRUG $21,858,864.00
- IBIO $375,000.00
- Revenue This Year
- TRUG $24.05
- IBIO $36.00
- Revenue Next Year
- TRUG $31.65
- IBIO N/A
- P/E Ratio
- TRUG N/A
- IBIO N/A
- Revenue Growth
- TRUG 6.19
- IBIO 650.00
- 52 Week Low
- TRUG $0.22
- IBIO $0.64
- 52 Week High
- TRUG $1.60
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- TRUG 36.70
- IBIO 24.07
- Support Level
- TRUG $0.21
- IBIO $0.75
- Resistance Level
- TRUG $0.25
- IBIO $0.82
- Average True Range (ATR)
- TRUG 0.03
- IBIO 0.14
- MACD
- TRUG -0.00
- IBIO 0.10
- Stochastic Oscillator
- TRUG 16.12
- IBIO 3.04
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.